A Phase 3 interventional study of Drospirenone in Contraception and Change in Bone Mineral Density, sponsored by Insud Pharma. Completed at 47 sites in 2 countries. Open to female participants aged 13 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Insud Pharma · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Contraception Behavior with a site in United States — 10 open to participants now, 18 under way, none of them phase 3. Contraception Behavior · United States.
Among the 70 studies in Contraception Behavior with a site in United States, this one is the 5th largest by enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2022, is one of 3 in phase 3, and was the 56th registered.
132 studies on the registry are indexed under Contraception Behavior; 20 are open to participants now.
Browse Contraception Behavior studies →10 of the 70 studies in Contraception Behavior with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 21–55 · Men only
University of Virginia · Sites in United States
Ages 18–44 · Women only · Healthy volunteers
Population Council · Sites in United States
Ages 18–49 · Women only · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 15–20 · Healthy volunteers
Child Trends · Sites in United States
Ages 12–15 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Contraception Behavior studies recruiting now, 3 (23%) set no upper age limit and 10 (77%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 13 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,542 is above the median of 382 across 106 interventional studies indexed under Contraception Behavior.
Median enrollment 279 across the 61 interventional studies, 75 across the 9 observational. Of the 48 that completed or were terminated, 19 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 70 have an industry lead sponsor. The 10 most frequent:
Insud Pharma is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Insud Pharma has 1 study filed under Contraception Behavior — fewer than ten, so there is no comparison to draw.
5 of the studies in Contraception Behavior with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05216003Indiana UniversityPregnancy at a Time That Is Happy and Healthy for You | 2026-12 |
| NCT05674513Oregon Health and Science UniversityDisparities in Emergency Contraceptive Metabolism Dictate Efficacy | 2026-12-31 |
| NCT07451067University of Pittsburgh"Vasectomy: Right for Me?" Decision Support Tool | 2027-08 |
| NCT05022134Children's Mercy Hospital Kansas CityEvaluating the Impact of CHOICE-AYA on Contraceptive Use, Continuation and Satisfaction | 2027-08-01 |
| NCT06990724Weill Medical College of Cornell UniversityEffectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents. | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 70 studies in Contraception Behavior with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113. The secondary objective of Part A is to evaluate the safety and tolerability of LPRI-CF113. The primary objective of Part B is to evaluate the impact of LPRI-CF113 on bone mineral density (BMD) at the lumbar spine (L1-L4) after 12 months (13 medication cycles). The secondary objective of Part B is to evaluate the impact of LPRI-CF113 on BMD and bone turnover after 12 months (13 medication cycles) at the femoral neck, total hip, and total body.
This is a Phase 3, prospective, multi-center, open-label, non-comparative study in female subjects 13 to 45 years of age (inclusive) to determine the efficacy, safety, and tolerability of LPRI-CF113 administered orally for 13 (28-day) medication cycles (Part A). Healthy, sexually active female subjects of childbearing potential, who present to the clinic seeking contraception, will be enrolled in the study.
Part B will be an investigation of bone mineral density (BMD) at the lumbar spine and BMD and bone turnover at the femoral neck, total hip, and total body. Part B will consist of a subgroup of subjects enrolled in Part A (i.e., subjects that meet all of Part A inclusion criteria and none of Part A AND Part B exclusion criteria) who are 18 to 45 years of age (inclusive at the time of screening). BMD will be assessed by dual-energy X-ray absorptiometry (DXA) scan.
The study duration (Parts A and B) for each subject will be up to approximately 404 days (28 days [screening] + 376 days [Treatment and Follow-up Period]), unless the subject meets criteria for the extended Part B Follow-up, in which the duration will be approximately 769 days (28 days [screening] + 376 days [Treatment and Follow-up Period] + 365 days [extended Part B Follow up]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must be female, healthy, sexually active, postmenarcheal, premenopausal, and of , between 13 and 45 years of age (inclusive at the time of screening) and at risk for pregnancy
Subjects must have a systolic blood pressure of 159 mmHg or lower and a diastolic blood pressure of 99 mmHg or lower
Subjects must be regularly menstruating (with cycle length between 21 and 35 days) for at least 3 months prior to the signing of the Informed Consent Form
Exclusion Criteria:
PART A:
The subject has a desire to become pregnant at the time of screening
The subject has received any of the following:
The subject at the time of screening has a history of primary amenorrhea or secondary amenorrhea (with or without known etiology)
The subject has an abnormal Pap smear finding of low-grade squamous intraepithelial lesion or higher at screening or 6 months prior to screening. Subjects \<21 years of age at screening do not require a Pap smear
The subject has a history of alcohol or substance use disorder within 12 months prior to screening. Alcohol abuse is defined as typical consumption of 14 or more alcoholic drinks weekly
Medications known to reduce the efficacy of hormonal contraceptives:
Other prohibited medications or products:
The subject has a history of severe or critical Coronavirus Disease 2019 (COVID-19) or has been hospitalized for COVID-19 within 3 months prior to screening
The subject has a history of or is currently being treated for any of the following:
PART B:
The subject has a history of medical conditions or procedures associated with low BMD. This includes the following:
The subject has a history of chronic (3 or more months) use within 12 months of screening of the following medications known to increase BMD:
The subject has a history of chronic (3 or more months) use within 12 months of screening of the following medications known to decrease BMD:
The subject has any of the following that may preclude accurate BMD measurement by DXA scan:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects enrolled in the study will participate in Part A of the study. Part A of the study will investigate the efficacy, safety, and tolerability of LPRI-CF113.
Drug: Drospirenone
A subgroup of subjects from Part A that are age 18-45 and without further exclusion criteria to Part B will be enrolled in Part B of the study. Part B of the study will investigate the effects of LPRI-CF113 on bone mineral density.
Drug: Drospirenone
LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
Also known as: LPRI-CF113
Part A (Efficacy Assessment): Number of pregnancies in subjects ≤35 years of age (at the time of screening).
Calculated by Pearl Index.
Time frame: 12 months
Part A (Efficacy Assessment): Number of pregnancies from exposure cycles in subjects ≤35 years of age.
Calculated by Pearl Index.
Time frame: 12 months
Part A (Efficacy Assessment): Number of pregnancies from method failures in subjects ≤35 years of age.
Calculated by Pearl Index.
Time frame: 12 months
Part A (Efficacy Assessment): Pregnancy ratio from evaluable cycles, exposure cycles, and perfect cycles in subjects ≤35 years of age.
Calculated by life table analysis.
Time frame: 12 months
Part A (Efficacy Assessment): Number of pregnancies from exposure cycles, method failures, and evaluable cycles in all subjects.
Calculated by Pearl Index.
Time frame: 12 months
Part A (Efficacy Assessment): Pregnancy ratio in all subjects.
Calculated by life table analysis.
Time frame: 12 months
Part A (Efficacy Assessment): Number of pregnancies from exposure cycles, method failures, and evaluable cycles in subjects >35 years of age.
Calculated by Pearl Index.
Time frame: 12 months
Part A (Efficacy Assessment): Pregnancy ratio in subjects >35 years of age.
Calculated by life table analysis.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence and severity of adverse events (AEs), adverse events of special interest (AESIs), drug-related AEs, and treatment-emergent AEs.
Can be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the intervention drug (LPRI-CF113). Counts and percentages of subjects with AEs will be presented by system organ class and preferred term with the severity reported.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence and severity of abnormal clinical findings on physical examination, gynecological examination, and transvaginal ultrasound examination.
The investigator will exercise his or her clinical judgement in deciding whether an abnormal assessment is clinically significant. The incidence and severity of abnormal clinical findings will be summarized with counts and percentages.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence and severity of mastodynia/mastalgia and dysmenorrhea.
The incidence and severity of abnormal clinical findings will be summarized with counts and percentages.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence and severity of abnormal cervical cytology.
Assessed by pap smear.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence and severity of abnormal bleeding.
The number of bleeding or spotting days will be summarized by medication cycle. The number of bleeding or spotting episodes, length of bleeding or spotting episodes, number of subjects with prolonged bleeding (\>14 days in a 90-day reference period), and incidence of unscheduled bleeding will be summarized.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence of clinical laboratory abnormalities from baseline, including chemistry, hematology, and urinalysis, considered significant by the Investigator.
Incidence of laboratory abnormalities will be summarized with counts and percentages.
Time frame: 12 months
Part A (Primary Safety Assessment): Incidence of vital sign abnormalities from baseline, including blood pressure, heart rate, respiratory rate, and body temperature, considered significant by the Investigator.
Absolute values and changes from baseline of vital signs will be summarized using descriptive statistics.
Time frame: 12 months
Part A (Primary Tolerability Assessment): Changes in quality of life.
Assessed by Q-LES-Q-SF (Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form)
Time frame: 12 months
Part A (Primary Tolerability Assessment): Acceptability of study drug.
All subjects will be asked by the Investigator via questionnaire: Are you satisfied with this oral contraceptive method? For subjects who suspended their oral contraceptive method in order to begin administration of the study drug, the Investigator will ask: How was your wellbeing during the intake of the study drug in comparison to the time when you took your formal contraceptive?
Time frame: 12 months
Part B (Primary Safety Assessment): Mean percentage change in lumbar spine (L1-L4) bone mineral density (BMD) in subjects ≥18 years of age.
BMD measured by dual-energy X-ray absorptiometry (DXA) scan.
Time frame: Baseline to 12 months
Part B (Secondary Safety Assessment): Mean absolute changes in lumbar spine (L1-L4) BMD in subjects ≥18 years of age.
BMD measured by DXA scan.
Time frame: Baseline to 12 months
Part B (Secondary Safety Assessment): Mean absolute and percentage changes in BMD (femoral neck, total hip, and total body) in subjects ≥18 years of age.
BMD measured by DXA scan.
Time frame: Baseline to 12 months
Part B (Secondary Safety Assessment): Mean absolute and percentage changes in BMD (lumbar spine, femoral neck, total hip, and total body) in subjects ≥18 years of age.
BMD measured by DXA scan.
Time frame: Baseline to 6 months
Part B (Secondary Safety Assessment): Mean absolute changes in BMD Z-scores (lumbar spine, femoral neck, total hip, and total body) in subjects ≥18 years of age.
BMD measured by DXA scan.
Time frame: Baseline to 6 months and 12 months
Part B (Secondary Safety Assessment): Proportion of subjects with percentage changes in lumbar spine, femoral neck, total hip, and total body BMD by categories in subjects ≥18 years of age.
BMD measured by DXA scan, categories defined as ≥0%, \<0% to -1.5%, \<-1.5% to -3%, \<-3% to -5%, \<-5% to -8%, and \<-8%.
Time frame: Baseline to 12 months
Part B (Secondary Safety Assessment): Proportion of subjects with absolute changes in BMD Z-scores (lumbar spine, femoral neck, total hip, and total body) in subjects ≥18 years of age.
BMD measured by DXA scan, categories defined as ≥0.5, \<0.5 to 0.3, \<0.3 to 0, \<0 to -0.3, \<-.3 to -0.5, and \<-0.5.
Time frame: Baseline to 6 months and 12 months
Ran from Aug 2022 to primary completion in Aug 2024, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Drospirenone
Insud Pharma